Comparisons of Clinical Outcomes in Women with Advanced Ovarian Cancer Treated with Frontline Intraperitoneal versus Dose-Dense Platinum/Paclitaxel Chemotherapy without Bevacizumab.

Szczegóły
Abstrakt

Tytuł:: Comparisons of Clinical Outcomes in Women with Advanced Ovarian Cancer Treated with Frontline Intraperitoneal versus Dose-Dense Platinum/Paclitaxel Chemotherapy without Bevacizumab.
Autorzy:: Ting WH; Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan.
Hsiao CH; Division of Medical Oncology and Hematology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan.
Chen HH; Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan.
Wei MC; Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan.
Lin HH; Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan.; Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei 100225, Taiwan.
Hsiao SM; Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan.; Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei 100225, Taiwan.; Graduate School of Biotechnology and Bioengineering, Yuan Ze University, Taoyuan 320315, Taiwan.
Źródło:: International journal of environmental research and public health [Int J Environ Res Public Health] 2020 May 20; Vol. 17 (10). Date of Electronic Publication: 2020 May 20.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Basel : MDPI, c2004-
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Fallopian Tube Neoplasms*/drug therapy
Ovarian Neoplasms*/drug therapy
Bevacizumab/administration & dosage ; Carboplatin ; Disease-Free Survival ; Female ; Humans ; Infusions, Parenteral ; Middle Aged ; Paclitaxel/administration & dosage ; Platinum/administration & dosage
References:: Cancer. 1981 Jan 1;47(1):207-14. (PMID: 7459811)
Gynecol Oncol. 2013 Jul;130(1):12-8. (PMID: 23578540)
Cancer Treat Rev. 2013 Apr;39(2):153-60. (PMID: 22595680)
Eur J Obstet Gynecol Reprod Biol. 2020 Jan;244:101-105. (PMID: 31778904)
Lancet. 2009 Oct 17;374(9698):1331-8. (PMID: 19767092)
Gynecol Oncol. 2020 Mar;156(3):530-534. (PMID: 31937450)
J Clin Oncol. 2001 Feb 15;19(4):1001-7. (PMID: 11181662)
Lancet Oncol. 2013 Sep;14(10):1020-6. (PMID: 23948349)
Gynecol Oncol. 2009 Jan;112(1):35-9. (PMID: 18977021)
Cancer Res. 2013 Jan 1;73(1):119-27. (PMID: 23108141)
J Natl Cancer Inst. 1997 Apr 2;89(7):480-7. (PMID: 9086004)
J Clin Oncol. 1989 Nov;7(11):1748-56. (PMID: 2681557)
Crit Rev Oncol Hematol. 2002 Dec 27;44 Suppl:S3-13. (PMID: 12505595)
J Clin Oncol. 2019 Jun 1;37(16):1380-1390. (PMID: 31002578)
N Engl J Med. 2016 Feb 25;374(8):738-48. (PMID: 26933849)
Gynecol Oncol. 2006 Jan;100(1):27-32. (PMID: 16368440)
Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1210-4. (PMID: 18284454)
Oncogene. 2016 Jan 14;35(2):261-8. (PMID: 25867070)
Eur J Obstet Gynecol Reprod Biol. 2020 Apr;247:257. (PMID: 32145996)
N Engl J Med. 1996 Dec 26;335(26):1950-5. (PMID: 8960474)
J Clin Oncol. 1996 May;14(5):1545-51. (PMID: 8622070)
Int J Gynaecol Obstet. 2001 Jan;72(1):55-60. (PMID: 11146078)
J Natl Cancer Inst. 2000 Sep 20;92(18):1534-5. (PMID: 10995813)
Gynecol Oncol. 2009 Sep;114(3):415-9. (PMID: 19577277)
N Engl J Med. 2006 Jan 5;354(1):34-43. (PMID: 16394300)
Jpn J Clin Oncol. 2011 Feb;41(2):278-82. (PMID: 20937602)
Contributed Indexing:: Keywords: adjuvant; chemotherapy; cytoreduction; ovarian neoplasms; peritoneum
Substance Nomenclature:: 2S9ZZM9Q9V (Bevacizumab)
49DFR088MY (Platinum)
BG3F62OND5 (Carboplatin)
P88XT4IS4D (Paclitaxel)
Entry Date(s):: Date Created: 20200524 Date Completed: 20201019 Latest Revision: 20201019
Update Code:: 20240105
PubMed Central ID:: PMC7277334
DOI:: 10.3390/ijerph17103603
PMID:: 32443934
: Czasopismo naukowe

Background: We aimed to compare the clinical outcomes between intraperitoneal chemotherapy and dose-dense chemotherapy for the frontline treatment of advanced ovarian, fallopian tube and primary peritoneal cancer in women not receiving bevacizumab. Methods: All consecutive women with stage II~IV cancer treated with either frontline intraperitoneal or dose-dense platinum/paclitaxel chemotherapy and not receiving bevacizumab between March 2006 and June 2019 were reviewed. Results: A total of 50 women (intraperitoneal group, n = 22; dose-dense group, n = 28) were reviewed. Median progression-free survival (32.6 months versus 14.2 months; adjusted hazard ratio = 0.38; 95% CI = 0.16 to 0.90, p = 0.03) and overall survival (not reached versus 30.7 months; adjusted hazard ratio = 0.23, 95% CI = 0.07 to 0.79, p = 0.02) were significantly higher in the intraperitoneal group than in the dose-dense group. A multivariable Cox proportional-hazards model also indicated that the number of frontline chemotherapy cycles (adjusted hazard ratio = 0.66, 95% CI 0.47 to 0.94, p = 0.02) was a predictor of better overall survival. Nausea/vomiting and nephrotoxicity occurred more frequently in the intraperitoneal group ( p = 0.02 and <0.0001, respectively). Conclusions: Intraperitoneal chemotherapy seems to be superior in progression free survival and overall survival to dose-dense chemotherapy in the frontline treatment of women with optimally resected advanced ovarian, fallopian tube or primary peritoneal cancer and not receiving bevacizumab.

Informacja